Latest Advances in the Management of Pediatric Gastrointestinal Stromal Tumors

Area of Science:

• Oncology
• Molecular Biology
• Pediatric Medicine

Background:

• Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the GI tract, typically affecting older adults.
• Pediatric GIST is rare and biologically distinct from adult GIST, often presenting wild-type status with mutations in SDH, TRK, RAS, or NF1 genes, unlike the common KIT and PDGFR mutations in adults.

Purpose of the Study:

• To review the latest management strategies for pediatric gastrointestinal tumors.
• To highlight advances in the molecular biology of pediatric GIST, focusing on resistance mechanisms.
• To discuss emerging targeted therapies, particularly next-generation kinase inhibitors, for pediatric GIST.

Main Methods:

• Literature review of recent studies on pediatric GIST management.
• Analysis of molecular alterations and their implications in pediatric GIST.
• Evaluation of current and emerging kinase inhibitor therapies for GIST.

Main Results:

• Pediatric GIST exhibits unique molecular profiles compared to adult GIST.
• Understanding these molecular differences is crucial for effective treatment selection.
• Higher-generation multikinase inhibitors show promise, with established efficacy in adults.

Conclusions:

• Individualized treatment approaches are essential for pediatric GIST due to distinct biology.
• Advances in molecular diagnostics enable better prediction of treatment response and resistance.
• Targeted therapies, including novel kinase inhibitors, represent a significant advancement in managing pediatric GIST.